Astellas Pharma: latest news - GoINPHARMA
Friday, 16 November 2018 - 19:14

Astellas Pharma

Astellas exploring selling Europe assets for $500m

Bloomberg yesterday evening reported that Japan-based Astellas Pharma is exploring selling its Central and Eastern Europe assets, worth at least $500m. Astellas’ management has already hired Jefferies Financial investment banking firm to look for a buyer. According to the report,…

Astellas announces plan of cutting at least 600 jobs

Japan-based pharmaceutical group Astellas has announced on a press release it will dismiss a minimum of 600 employees in Japan, especially in Research, but also partly in Marketing and Sales. The measure will result in closing down Astellas Research Technologies,…

Astellas announces acquisition of Universal Cells for $102.5m

Japan-based Astellas Pharma has announced today to the Japanese stock exchange authorities that it has acquired Universal Cells for $102.5m. Universal Cells is headquartered in Seattle and, over the years, has developed the Universal Donor Cell technology, based on stem…

Astellas acquires Mitobridge, worth $450m

Japan-based Astellas has acquired Mitobridge for $165.5m. Mitobridge is a biotech company headquartered in Cambridge (Massachusetts), focusing on the development of small molecules that target mitochondrial function. The deal includes an upfront $225m payment, plus an additional $225m payment based…

Astellas Pharma to close down Agensys center with 220 employees

Astellas Pharma, Japan-based pharmaceutical group focusing on urology, oncology, immunology and nephrology, yesterday announced on a press release it plans to wind down the Santa Monica, California-based Agensys center, focusing on ADC (Antibody-Drug Conjugate). The facility has 220 employees, whose…

Astellas pursuing M&A again: Ogeda acquired for €800m

Japan-based Astellas Pharma announced today before trading opened in Tokyo that it has acquired Belgium-based Ogeda SA for €800m. Ogeda develops novel drugs which bind to GPCR receptors. Its lead investigational product is fezolinetant, a non-hormonal therapy which has delivered…

Record year for German biotechs

2016 has brought highly satisfying results to Germany-based biotechs: Morphosys is obtaining very good clinical results. Aicuris (Wuppertal) has convinced many investors with highly positive data on novel antivirals. Ganymed has obtained results so satisfactory from its intestine cancer treatment…